OPKO Health, Inc. Business Acquisition, Cost of Acquired Entity, Liabilities Incurred (Deprecated 2013-01-31)
OPKO Health, Inc. (OPK) had Business Acquisition, Cost of Acquired Entity, Liabilities Incurred (Deprecated 2013-01-31) of $600.00 thousand as of 2011-01-31, per its 10-K filed 2013-03-18.
Discontinued › Notes › Business Combinations
us-gaap:BusinessAcquisitionCostOfAcquiredEntityLiabilitiesIncurred · last filed 2013-03-18
- 2011-01-31: Business Acquisition, Cost of Acquired Entity, Liabilities Incurred (Deprecated 2013-01-31) $600.00K.
- 2011-01-28: Business Acquisition, Cost of Acquired Entity, Liabilities Incurred (Deprecated 2013-01-31) $600.00K.
| Period end | Business Acquisition, Cost of Acquired Entity, Liabilities Incurred (Deprecated 2013-01-31) |
|---|---|
| 2011-01-31 | $600.00K 10-K · filed 2013-03-18 |
| 2011-01-28 | $600.00K 10-Q · filed 2012-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |